Search Results
Mar 10, 2026, 10:00 ET Integrity Partnership Accelerates Impact for MG3 Enterprises Offering Proprietary Technology Platform
information about MG3 Enterprises' partnership with Integrity, view a video at www.integrity.com/MG3.About
More news about: Integrity Marketing Group, LLC
Mar 10, 2026, 09:07 ET GOLDFLOWER LAUNCHES SPACE COAST NRGY CHEWS, A NEW EDIBLE DESIGNED FOR DAYTIME USE
combine vibrant fruit-inspired flavors with functional terpene blends designed to complement a bright, positive experience. Each chew contains 10mg of THC, with 100mg per package, providing patients with a consistent and approachable edible format suited for daytime use. "Patients are increasingly looking
More news about: Goldflower Cannabis
Mar 10, 2026, 08:47 ET Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
therapy. LYMPHIR was administered intravenously on Days 1–3 of each 21‑day cycle at escalating doses (3, 6, 9, and 12 mcg/kg), along with pembrolizumab (200 mg IV) on Day 1. Patients who completed eight cycles of combination therapy were continued on pembrolizumab monotherapy until disease progression.The
More news about: Citius Oncology, Inc.
Mar 10, 2026, 06:59 ET Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
bempikibart for 36 weeks, with follow-up out to 52 weeks. Dosing includes an initial loading regimen of 200mg of bempikibart dosed weekly for four doses, followed by a maintenance dose of 200mg every-other-week over a 32-week period for a total dosing period of 36 weeks. Efficacy will be evaluated on
More news about: Q32 Bio
Mar 10, 2026, 06:00 ET Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
obese patients in this study while formulation A2 did not.For ASC30 SQ depot formulation A1, all participants were given three SQ doses of 400 mg each with a four-week dosing interval at day 1, day 29 (week 4) and day 57 (week 8). ASC30 SQ depot formulation A1 achieved placebo-adjusted mean body
More news about: Ascletis Pharma Inc.
Mar 10, 2026, 03:36 ET Stratégie de Risen Energy en matière de faible teneur en argent pour la technologie HJT : une feuille de route à long terme
production depuis plusieurs années. Actuellement, la consommation d'argent pur des cellules HJT de Risen Energy a été réduite à 3,9 milligrammes par watt (mg/W), un niveau qui est à l'avant-garde à l'échelle mondiale.III. Réflexions et perspectives d'avenir : des progrès fondés sur la valeur Cette
More news about: Risen Energy Co., Ltd
Mar 10, 2026, 03:33 ET The 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard
(C4B) in Texas produces ProPure™ endotoxin-free proteins with levels below the quantification limit (BQL) (< 0.05 EU/mg), which exceed the industry standard (0.5 EU/mg according to USP <85>). Choosing ProPure™ proteins supports accurate experimental outcomes, enhances data reliability,
More news about: Sino Biological, Inc.
Mar 10, 2026, 03:22 ET The 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard
(C4B) in Texas produces ProPure™ endotoxin-free proteins with levels below the quantification limit (BQL) (< 0.05 EU/mg), which exceed the industry standard (0.5 EU/mg according to USP <85>). Choosing ProPure™ proteins supports accurate experimental outcomes, enhances data reliability,
More news about: Sino Biological, Inc.
Mar 09, 2026, 12:24 ET Strategie společnosti Risen Energy pro technologii HJT s nízkým obsahem stříbra: dlouhodobý plán
V současné době byla spotřeba čistého stříbra v článcích heterojunkční technologie (HJT) společnosti Risen Energy snížena na 3,9 miligramů na watt (mg/W), což je úroveň, která je na špičce celosvětového žebříčku.III. Reflexe a výhled do budoucna: pokrok založený na hodnotách Tento
More news about: Risen Energy Co., Ltd
Mar 09, 2026, 12:20 ET Stratégia Risen Energy pre technológiu HJT s nízkym obsahom striebra: dlhodobý plán
výrobných linkách už niekoľko rokov. V súčasnosti sa spotreba čistého striebra v článkoch HJT spoločnosti Risen Energy znížila na 3,9 miligramov na watt (mg/W), čo je v celosvetovej mierke na poprednej úrovni.III. Úvahy a výhľad do budúcnosti: pokrok zameraný na hodnoty Táto analýza zdôrazňuje
More news about: Risen Energy Co., Ltd
Mar 09, 2026, 10:50 ET CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
treatment for the condition has ever been approved.In the study, 36 patients were randomized to HLP004 20 mg or 2 mg and received two intramuscular doses three weeks apart. Patients receiving 20 mg adjunctive to standard of care achieved a mean HAM-A reduction of 10.4 points (p<0.0001) at six weeks.
More news about: USA News Group
Mar 09, 2026, 08:39 ET Jeonbuk National University Researchers Develop an AI Model For Personalized Blood Glucose Monitoring
prediction error compared to conventional models. Notably, the prediction error varied from an excellent 19.64 milligram/decilitre (mg/dL) for one patient to a challenging 30.57 mg/dL for another. While these results represent a clear improvement over the standard LSTM models, they also highlight the persistent
More news about: Jeonbuk National University
Mar 09, 2026, 08:37 ET Die Strategie für einen geringen Silberanteil von Risen Energy für die HJT-Technologie: Eine langfristige Roadmap
großem Maßstab auf Produktionslinien hergestellt. Derzeit wurde der reine Silberverbrauch der HJT-Zellen von Risen Energy auf 3,9 Milligramm pro Watt (mg/W) reduziert, ein Wert, der weltweit führend ist.III. Reflexionen und Ausblick: Wertorientierter Fortschritt Diese Übersicht hebt
More news about: Risen Energy Co., Ltd
Mar 09, 2026, 08:34 ET Estrategia de Risen Energy para el uso de plata en la tecnología HJT: una hoja de ruta a largo plazo
producción durante varios años. Actualmente, el consumo de plata pura de las células HJT de Risen Energy se ha reducido a 3,9 miligramos por vatio (mg/W), un nivel líder a nivel mundial.III. Reflexiones y perspectivas de futuro: Progreso basado en valoresEsta
More news about: Risen Energy Co., Ltd
Mar 09, 2026, 08:30 ET Strategia ograniczania zużycia srebra w technologii HJT firmy Risen Energy: plan długoterminowy
produkcyjnych już od kilku lat. Obecnie zużycie czystego srebra w ogniwach HJT firmy Risen Energy zostało obniżone do poziomu 3,9 miligrama na wat (mg/W), co stanowi jeden z najlepszych wyników na świecie.III. Wnioski i perspektywy na przyszłość: postęp oparty na wartościNiniejszy
More news about: Risen Energy Co., Ltd
Mar 09, 2026, 08:01 ET Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
10).In the Phase 2b trial segment, 32 patients with CDI were enrolled and randomized in a 1:1 ratio to either ibezapolstat 450 mg every 12 hours or vancomycin 125 mg orally every 6 hours, in each case, for 10 days and followed for 28 ± 2 days following the end of treatment for recurrence of CDI.
More news about: Acurx Pharmaceuticals, Inc.
Mar 09, 2026, 08:00 ET AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
a Doses from 2mg to 14mg were tested using different dose escalations and dosing frequencies.
More news about: AbbVie
Mar 09, 2026, 08:00 ET Risen Energy's Low-Silver Strategy for HJT Technology: A Long-Term Roadmap
production lines for multiple years. Currently, the pure silver consumption of Risen Energy's HJT cells has been reduced to 3.9 milligrams per watt (mg/W), a level that is at the forefront globally.III. Reflections and Future Outlook: Value-Driven Progress This review highlights three
More news about: Risen Energy Co., Ltd
Mar 09, 2026, 08:00 ET ITF Therapeutics LLC Presents New Data and Analyses on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2026 MDA Clinical and Scientific Conference
Monitor triglycerides at 1 month, 3 months, 6 months, and then every 6 months thereafter. Modify the dosage if fasting triglycerides are verified >300 mg/dL. Treatment with DUVYZAT should be discontinued if triglycerides remain elevated despite adequate dietary intervention and dosage adjustment.Gastrointestinal Disturbances:
More news about: ITF Therapeutics LLC
Mar 09, 2026, 05:29 ET India Luxury Car Market to Reach USD 9.19 Billion by 2032, Driven by Rising Premiumization and Strong Demand for Luxury SUVs, Says MarkNtel Advisors
networks, and specialized service centers operated by leading global automakers. For instance:2025: MG Motor India inaugurated its first MG Select premium dealership in Delhi, marking the launch of its luxury retail channel designed to offer a premium customer experience
More news about: MarkNtel Advisors
Mar 06, 2026, 09:56 ET LOOKING FOR NEW, NUTRITIOUS MEAL IDEAS THAT THE WHOLE FAMILY WILL LOVE? SWAP IN POTATOES!
is a nutrient-dense vegetable that has:Nearly 1/3 of your daily recommended Vitamin C.620 mg of potassium, which is more than a banana (422 mg)3g of protein, 2g of fiber, iron, and vitamin B6!In this segment, Kelly Jones shares a few of her favorite
More news about: Potatoes USA
Mar 06, 2026, 08:00 ET Daylight Saving Time Stole Your Hour--Wendy's Has the Comfort Food Cure
bed*.More caffeine please. Wendy's Cherry Limeade Sparkling Energy* or Pineapple Citrus Sparkling Energy* are packed with B-12 vitamins and 80-120 mg of caffeine.Mid-day slump hitting hard? A Chicken Tenders Ranch Wrap** or a Jr. Bacon Cheeseburger Biggie Bag® can help fans power through
More news about: The Wendy's Company
Mar 06, 2026, 08:00 ET Aisa Pharma Announces Encouraging Results from Phase 2 RECONNOITER Trial of AISA-021 (Cilnidipine) in Patients with Systemic Sclerosis-Associated Raynaud's Phenomenon
active SSc RP. The study enrolled a total of 64 patients and was conducted in two parts, Part A, a Phase 2A parallel arm design to evaluate dose (10 mg and 20 mg), safety, efficacy, and co-administration with a PDE-V inhibitor, and Part B, a Phase 2 randomized crossover design to evaluate safety and efficacy
More news about: Aisa Pharma
Mar 06, 2026, 04:20 ET Foresee Pharmaceuticals Welcomes Positive CHMP Opinion Recommending Approval of CAMCEVI 21mg, 3-month strength in the European Union for Advanced Prostate Cancer
new 21 mg, 3-month ready-to-use strength of the long-acting injectable formulation for the treatment of advanced prostate cancer. This CHMP positive opinion is a regulatory milestone for patients living with advanced prostate cancer and the healthcare providers who treat them. CAMCEVI 21 mg is a
More news about: Foresee Pharmaceuticals Co., Ltd.
Mar 06, 2026, 01:36 ET Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Chronic Weight Management
obesity.Using the treatment policy estimand, at week 48, Ecnoglutide demonstrated dose-dependent weight loss, with the highest dose (2.4 mg) achieving a mean 15.4% (placebo-adjusted 15.1%) reduction from baseline and 92.8% of participants achieving clinically meaningful ≥5% weight loss - nearly
More news about: Sciwind Biosciences Co., Ltd.